UPDATED: No Approval for Dexcom Verily G1
Yesterday, FENIX observed a J.P. Morgan analyst research publication from earlier in the week that reported Dexcom’s Verily G1 received approval based on an FDA 510(k) posting entitled “Dexcom G6 Glucose Program Continuous Glucose Monitoring System”. The research publication seemed highly credible since it was produced by the award-winning J.P. Morgan healthcare research analyst team and the FDA source was publicly available. Later, J.P. Morgan analyst Robbie Marcus admitted the incorrect reporting of the Verily G1 approval in a subsequent publication. Below are screenshots from each J.P. Morgan publication obtained by FENIX.
About The Author
Matthew has been a thought leader in the high-growth therapeutic areas of diabetes and cardiovascular medicine since 2006, making regular attendance at large and small CV/met scientific meetings and an architect of novel methods for assessing market opportunities. He has over a decade of experience in leading CV/met consulting engagements, is a published author in PM360 and Diabetes Technology & Therapeutics, and has been quoted in The Pink Sheet on anti-thrombotics.
If you receive our email blasts, you already have an account. Log in now
You can read the article’s full content online after purchase.